Test Predicts Benefit of Chemo in ER +, HER2 − Breast Cancer

WEDNESDAY, May 8, 2019 -- EndoPredict (EPclin) is prognostic for distant recurrence (DR) in women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, according to a study published online April 30...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

AbstractPurpose of reviewThis paper will focus on novel breast cancer therapies used in clinical practice today, as well as review our understanding of standard therapies and their potential impact on cardiovascular health.Recent findingsEstablished and novel treatments such as anthracyclines, HER2-targeted agents, and immunotherapy have contributed to improvements in breast cancer outcomes; however, these treatments may be associated with an increased risk of cardiovascular injury. The number of available breast cancer treatments continues to expand, as does the need for health care providers to understand the potential i...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
Different conclusions have been drawn from similar findings, perhaps as a result of subjective margins for equivalence in HER2+ breast cancer research.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Authors: Exman P, Pernas S, Tolaney SM PMID: 31188804 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Conclusion: The DCTDR strategy provides a simple, pragmatic and enzyme-free toolbox to conveniently and sensitively analyze protein status in clinical samples for improving clinical research, cancer diagnostics and personalized treatment.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusions: Our findings suggest that miR-4306 acts as a tumor suppressor in TNBC and is a potential therapeutic target for TNBC treatment.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusion: This translational study identified CXCL5 as a biomarker of efficacy of lysosomotropic drugs, a potential asset for personalized medicine.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Conclusions: We postulate that the well-controlled dynamic pathway EZH2-H3K27me3-TET1 is a novel epigenetic co-regulator module and provide evidence regarding how to exploit it as a novel therapeutic target via its pivotal role in senescence and apoptosis control. Of clinical and therapeutic significance, the present study opens a new avenue for TNBC treatment by targeting the EZH2-H3K27me3-TET1 pathway that can modulate the epigenetic landscape.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Publication date: Available online 12 June 2019Source: European Journal of RadiologyAuthor(s): G Santamaría, X Bargalló, S G Ganau, I Alonso, M Muñoz, M Mollà, PL Fernández, A PratABSTRACTOBJECTIVES: To validate the performance of multiparametric magnetic resonance (MR) imaging to assess pathologic response to neoadjuvant systemic therapy (NST) in various breast cancer subtypes considering two definitions of pCR: absence of any residual invasive cancer or DCIS (ypT0) and absence of invasive tumour cells (ypT0/is).METHODSInstitutional review board–approved retrospective study, with w...
Source: European Journal of Radiology - Category: Radiology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Pharmaceuticals | Study | Women